Introduction
In general, ulcerative colitis (UC) is defined as idiopathic inflammation limited to the colorectum, except for backwash ileititis and postcolectomy pouchitis. However, UC is also considered to be a systemic disease because of not only colonic inflammation but also joint, skin, and acute hepatic involvement. Recently, there have been several reports of UC patients with gastroduodenitis or enteritis [1] [2] [3] [4] . Cases of gastroduodenitis or enteritis associated with UC are clinically rare but are an important issue for gastroenterologists in the point of no optimal treatment established. Here, we report a case of the postoperative occurrence of small-intestinal inflammation associated with UC successfully treated with infliximab.
Case Report
A 19-year-old female was referred to our hospital in January of 2007 because of severe abdominal pain and hematochezia. Four years before admission, she had been diagnosed with ulcerative colitis (pancolitis type) both endoscopically and histologically. She was treated with oral salazosulfapyridine and corticosteroids. However, she required a dose-up of corticosteroids, mesalamine, and granulocytapheresis because she did not achieve remission. However, in January of 2007, the patient was readmitted to our hospital because of exacerbation of her UC condition. After the additional treatment with tacrolimus and azathioprine (AZA), her symptom was improved and corticosteroids were gradually tapered off and completely stopped after 5 months, but the patient was readmitted because of relapse of her UC in September of 2007. Upon admission, her body temperature was 37.3°C and laboratory data showed slight anemia and mild elevation of C-reactive protein (CRP) (WBC 6,300/mm 3 , RBC 374 9 10 4 /mm 3 , Hb 11.8 g/dl, Ht 36.2%, CRP 0.4 mg/dl). Colonoscopy disclosed diffuse edema, loss of vascular pattern, and easy bleeding from the rectum up to cecum. The serology test, immunohistochemistry, and mucosal PCR were negative for cytomegalovirus. Both esophago-gastro-duodenoscopy (EGD) and radiographic visualization of the small intestine revealed normal findings. Histological examination showed no infiltration of inflammatory cells in gastroduodenal mucosa. Since she repeated a flare-up of her UC despite the use of immunomodulators, proctocolectomy with IPAA (ileal-pouch-anal anastomosis) and a temporary diverting ileostomy were performed at the end of September. Histological diagnosis of the colectomy specimen was compatible with pancolitis UC, and no inflammation or granuloma were detected in the terminal ileum. The postoperative course was uneventful and her condition was stable without any medication.
In February of 2008, however, she was admitted again because of frequent vomiting and severe epigastralgia at 65 days after colectomy. EGD revealed edema and granularity in the duodenal bulb and the second portion of the duodenum (Fig. 1 ). Histological examination taken from the duodenum showed neutrophil infiltration in the submucosa and cryptisis with no findings of non-caseous granuloma (Fig. 2) . Also, neither villous atrophy nor crypt hypertrophy was observed in the biopsy specimen, which suggested no possibility of celiac disease or autoimmune enteropathy of her disease. Immunohistochemistry and serological test were negative for H. pylori. Stool culture was also negative for Clostridium difficile. Taken together, we diagnosed her as having duodenitis associated with UC. Her abdominal pain deteriorated despite the prompt treatment with mesalamine. An abdominal CT revealed the marked distention and wall thickening and edema of the small intestine (Fig. 3) , which was suggestive of the occurrence of small-intestinal inflammation associated with UC. Additionally, pouch endoscopic findings revealed diffuse edema, loss of vascular pattern, and small erosions with pus in the pouch. Histological findings of biopsy specimen were compatible with pouchitis. Infliximab (IFX) (5 mg/kg) was promptly initiated. She responded rapidly to this treatment, and EGD at 109 days after administration of IFX revealed significant improvement of duodenitis when seen in June of 2008 (Fig. 4) . Pouch endoscopy also revealed improvement of her pouchitis. We performed intracellular cytokine assay with peripheral CD4 T cells before and after IFX therapy. The ratio of T-helper (Th) 1 (IFN-c)/Th2 (interleukin (IL)-4) was increased (31.7) at 2 weeks after IFX therapy compared to that before (14.5). She was in clinical remission with maintenance therapy of IFX. Fig. 1 Esophago-gastroduodenoscopy disclosed edema, granularity in the duodenal bulb (a, b) and the second portion of the duodenum (c) Fig. 2 Histological examination taken from the duodenum showed neutrophil infiltration in the submucosa and cryptisis with no findings of non-caseous granuloma
Discussion
Gut inflammation in UC has been considered to be limited to the large bowel. Several cases of UC with gastrointestinal involvement have been reported [5] [6] [7] . Rubstein et al. reported five UC cases with duodenal and jejunal involvements [7] . Hori et al. reported the prevalence (19/250: 7.6%) and significant risk factors (pancolitis and a lower dose of predonisolone) of gastroduodenitis-associated UC by performing prospective esophagogastroduodenoscopy for 250 Japanese patients with UC [8] . Since the endoscopic features mimicking those of colon are sometimes helpful for making diagnosis of gastroduodenitis related to UC, EGD is available for examining whether gastroduodenitis would occur in patients with UC after colectomy [9, 16] . It was reported that duodenitis associated with UC occurred after colectomy tends to be accompanied by pouchitis as in our present case [9] . These reports suggested that both EGD and pouch endoscopy should be performed when patients with UC taking colectomy complain of abdominal symptoms.
Thus, much attention is focused on UC patients with gastroduodenitis or enteritis, although the etiology is still unknown. Recently, Gooding et al. reported eight cases of idiopathic small-intestinal inflammation after colectomy for UC including their own case [9] . In seven out of eight cases, immunosuppressive therapies such as corticosteroids or azathioprine were effective. Finally, they concluded that patients with idiopathic small-intestinal inflammation should be treated by immunosuppressants promptly after the diagnosis was made because these patients responded well to immunosuppressive therapies.
However, no standard therapy for patients with smallintestinal inflammation associated with UC has been established yet. In the present case, our patient was promptly treated with a combination of IFX and 3 days methylprednisolone at diagnosis of panenteritis after colectomy. The reason why we administered IFX alternative to immunomodulators is due to that she had experienced flare-ups of her UC several times before colectomy, irrespective of using immunomodulators such as AZA and tacrolimus. At present, she maintained clinical remission with maintenance therapy of IFX after completely tapering off corticosteroid. It is well known that IFX, a chimeric monoclonal antibody directed against tumor necrosis factor-a, is effective for patients with Crohn's disease and UC [10] [11] [12] . However, whether IFX can be effective for UC patients with small-intestinal inflammation after colectomy remains unclear. In the present case, interestingly, the patient's abdominal symptoms subsided with the increase of the Th1/Th2 ratio of peripheral CD4 T cells after administration of IFX. This intracellular cytokine data suggested that the pathophysiology of small-intestinal inflammation occurred after colectomy in patients with UC might be associated with a Th2 cytokine phenotype. Our several reports showed that skewing toward the Th1 cytokine profile could lead to a reduction of disease activity of UC [13] [14] [15] . Therefore, we expect IFX to be a promising therapy for small-intestinal inflammation associated with UC because of its immunomodulative effect, but it is necessary to perform clinical trials with IFX for a larger number of patients with small-intestinal inflammation associated with UC.
In conclusion, this is the first case of a patient with postoperative occurrence of small-intestinal inflammation associated with UC successfully treated with IFX. Most importantly, if we encounter patients with UC who complained of unexplained abdominal pain and diarrhea after undertaking colectomy, we should consider the occurrence of small-intestinal inflammation as a differential diagnosis because prompt diagnosis results in an excellent outcome.
